Combinatorial lipid chemistry offers a novel approach to improving the therapeutic effects and delivery characteristics of both known and novel compounds. Amarin has researched and patented how to use different types of chemical linkage to attach a range of bioactive lipids either to other lipids or other drugs. The results are novel single chemical entities with predictable properties, potentially offering substantial and clinically relevant advantages over either compound alone.


Such advantages include the following:

• entirely new therapeutic actions
• improvements in existing therapeutic actions
• improved oral bioavailability
• better penetration into cells, across skin and into the brain
• pro-drugs with variable rates of release of the active moiety
• rapid development timescales

This technology has application across a broad range of therapeutic areas including CNS, cardiovascular, gastrointestinal and oncology. The lead porgram from this technology platform is AMR103, a novel form of levodopa at pre-clinical stage of development of Parkinson's disease.

This page was last updated on May 30, 2008.